Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

You may be eligible if

• Male patients with chemotherapy naive metastatic castration resistant prostate cancer\*
• Age at least 18 years
• Patients from who it is possible to collect blood samples
• Patient who are able and willing to give written informed consent prior to screening and enrollment
• Life expectancy of \> 6 months
• Measurable disease \*definition of CRPC according to EAU guidelines 2014